A Randomized, Double-blind, Placebo-controlled, 6-week, Crossover Study to Examine the Effects of Tiotropium (Spiriva HandiHaler, 18 microg Once Daily) on Dynamic Hyperinflation and Physical Exercise Capacity in Patients With Early Stage Chronic Obstructive Pulmonary Disease (COPD).

Trial Profile

A Randomized, Double-blind, Placebo-controlled, 6-week, Crossover Study to Examine the Effects of Tiotropium (Spiriva HandiHaler, 18 microg Once Daily) on Dynamic Hyperinflation and Physical Exercise Capacity in Patients With Early Stage Chronic Obstructive Pulmonary Disease (COPD).

Completed
Phase of Trial: Phase IV

Latest Information Update: 11 Sep 2013

At a glance

  • Drugs Tiotropium bromide (Primary)
  • Indications Chronic obstructive pulmonary disease
  • Focus Therapeutic Use
  • Sponsors Boehringer Ingelheim Pharmaceuticals
  • Most Recent Events

    • 11 Sep 2013 Results for the effect of tiotropium bromide on spontaneous expiratory flow-volume curves presented at the 23rd Annual Congress of the European Respiratory Society.
    • 05 Sep 2012 Results presented at the 22nd Annual Congress of the European Respiratory Society.
    • 31 Aug 2012 Results will be presented at the 2012 European Respiratory Society Congress according to a Boehringer Ingelheim media release. Results were also summarised in the media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top